Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks

Sin Gon Kim, Kyoung Jin Kim, Kun Ho Yoon, Sung Wan Chun, Kyong Soo Park, Kyung Mook Choi, Soo Lim, Ji Oh Mok, Hyoung Woo Lee, Ji A. Seo, Bong Soo Cha, Mi Kyung Kim, Ho Sang Shon, Dong Seop Choi, Doo Man Kim

Research output: Contribution to journalArticle

Abstract

We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were −0.79% and −0.86%, respectively; the between-group difference was 0.08% (95% confidence interval, −0.14% to 0.30%), showing non-inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (−11.9% vs. −4.8%; P <.0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add-on to metformin in terms of efficacy and safety.

Original languageEnglish
Pages (from-to)1869-1873
Number of pages5
JournalDiabetes, Obesity and Metabolism
Volume22
Issue number10
DOIs
Publication statusPublished - 2020 Oct 1

Keywords

  • clinical trial
  • lobeglitazone
  • randomized trial
  • thiazolidinediones
  • type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks'. Together they form a unique fingerprint.

  • Cite this

    Kim, S. G., Kim, K. J., Yoon, K. H., Chun, S. W., Park, K. S., Choi, K. M., Lim, S., Mok, J. O., Lee, H. W., Seo, J. A., Cha, B. S., Kim, M. K., Shon, H. S., Choi, D. S., & Kim, D. M. (2020). Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks. Diabetes, Obesity and Metabolism, 22(10), 1869-1873. https://doi.org/10.1111/dom.14085